USP 9 X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma

The mitotic spindle assembly checkpoint (SAC) maintains genome stability and marks an important target for antineoplastic therapies. However, it has remained unclear how cells execute cell fate decisions under conditions of SAC-induced mitotic arrest. Here, we identify USP9X as the mitotic deubiquitinase of the X-linked inhibitor of apoptosis protein (XIAP) and demonstrate that deubiquitylation and stabilization of XIAP by USP9X lead to increased resistance toward mitotic spindle poisons. We find that primary human aggressive B-cell lymphoma samples exhibit high USP9X expression that correlate with XIAP overexpression. We show that high USP9X/XIAP expression is associated with shorter event-free survival in patients treated with spindle poison-containing chemotherapy. Accordingly, aggressive B-cell lymphoma lines with USP9X and associated XIAP overexpression exhibit increased chemoresistance, reversed by specific inhibition of either USP9X or XIAP. Moreover, knockdown of USP9X or XIAP significantly delays lymphoma development and increases sensitivity to spindle poisons in a murine El-Myc lymphoma model. Together, we specify the USP9X–XIAP axis as a regulator of the mitotic cell fate decision and propose that USP9X and XIAP are potential prognostic biomarkers and therapeutic targets in aggressive B-cell lymphoma.

[1]  A. Rosenwald,et al.  Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis , 2014, Nature Medicine.

[2]  M. Gleave,et al.  Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer , 2014, Proceedings of the National Academy of Sciences.

[3]  M. Pagano,et al.  The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. , 2014, Biochimica et biophysica acta.

[4]  Kejian Zhang,et al.  Clinical Flow Cytometric Screening of SAP and XIAP Expression Accurately Identifies Patients with SH2D1A and XIAP/BIRC4 Mutations. , 2014, Cytometry. Part B, Clinical cytometry.

[5]  W. Wilson,et al.  Treatment strategies for aggressive lymphomas: what works? , 2013, Hematology. American Society of Hematology. Education Program.

[6]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[7]  L. Pasqualucci.  The genetic basis of diffuse large B-cell lymphoma , 2013, Current opinion in hematology.

[8]  N. Mailand,et al.  Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling , 2013, EMBO molecular medicine.

[9]  Christian Langer,et al.  SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma , 2012, Nature Cell Biology.

[10]  Stephen S. Taylor,et al.  The Spindle Assembly Checkpoint , 2012, Current Biology.

[11]  A. Strasser,et al.  The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. , 2012, Molecular cell.

[12]  L. Staudt,et al.  Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.

[13]  Simone Fulda,et al.  Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.

[14]  M. Malumbres,et al.  Killing cells by targeting mitosis , 2012, Cell Death and Differentiation.

[15]  G. Lenz,et al.  The molecular biology of diffuse large B-cell lymphoma , 2011, Therapeutic advances in hematology.

[16]  R. Medema,et al.  Mitosis as an anti-cancer target , 2011, Oncogene.

[17]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[18]  Yonghong Xiao,et al.  SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction , 2011 .

[19]  N. Donato,et al.  Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.

[20]  P. Clarke,et al.  Phosphorylation of Mcl‐1 by CDK1–cyclin B1 initiates its Cdc20‐dependent destruction during mitotic arrest , 2010, The EMBO journal.

[21]  Dirk Hasenclever,et al.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Weiner,et al.  Rituximab: mechanism of action. , 2010, Seminars in hematology.

[23]  Michael J. Clague,et al.  Emerging roles of deubiquitinases in cancer‐associated pathways , 2010, IUBMB life.

[24]  F. Bazan,et al.  Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival , 2010, Nature.

[25]  J. B. Garrison,et al.  XIAP mediates NOD signaling via interaction with RIP2 , 2009, Proceedings of the National Academy of Sciences.

[26]  D. Marmer,et al.  Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. , 2009, Clinical immunology.

[27]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[28]  Michele Pagano,et al.  The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint , 2008, Cell.

[29]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[30]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[31]  Vishva M Dixit,et al.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. , 2007, Cell.

[32]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[33]  F. Rieux-Laucat,et al.  XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome , 2006, Nature.

[34]  L. Medeiros,et al.  Expression of inhibitor of apoptosis proteins in B‐cell non‐Hodgkin and Hodgkin lymphomas , 2006, Cancer.

[35]  Yixian Zheng,et al.  Chromosome Alignment and Segregation Regulated by Ubiquitination of Survivin , 2005, Science.

[36]  David L. Vaux,et al.  IAPs, RINGs and ubiquitylation , 2005, Nature Reviews Molecular Cell Biology.

[37]  S. Korsmeyer,et al.  Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells , 2005, Science.

[38]  D. Vaux,et al.  XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland , 2005, Cell Death and Differentiation.

[39]  S. Wood,et al.  The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin. , 2004, Molecular biology of the cell.

[40]  Xiaodong Wang,et al.  A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. , 2004, Science.

[41]  S. Srinivasula,et al.  Mechanism of XIAP-mediated inhibition of caspase-9. , 2003, Molecular cell.

[42]  Stephanie Birkey Reffey,et al.  Characterization of XIAP-Deficient Mice , 2001, Molecular and Cellular Biology.

[43]  R. Liddington,et al.  Structural Basis for the Inhibition of Caspase-3 by XIAP , 2001, Cell.

[44]  S. Srinivasula,et al.  Structural Basis of Caspase-7 Inhibition by XIAP , 2001, Cell.

[45]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[46]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[47]  K. Kaibuchi,et al.  The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[48]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[49]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[50]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.